Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin (FSH/LH) preparation presented as an injection for subcutaneous use. It treats infertility related to anovulation, supports controlled ovarian stimulation in assisted reproductive technology, and addresses hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menopur is used in reproductive medicine to stimulate follicular development and ovulation.

- Infertility due to anovulation: enhances follicle growth and ovulation to improve chances of conception. - Controlled ovarian stimulation for assisted reproductive technology (ART): provides coordinated FSH and LH activity to produce multiple mature oocytes for IVF or ICSI cycles. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal ovarian function and estrogen production.

Menopur may cause a range of adverse reactions, which are generally related to its hormonal activity and injection site.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Mild ovarian hyperstimulation syndrome: abdominal bloating and mild nausea. - Headache: transient headache episodes. - Nausea: occasional nausea without vomiting.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, significant abdominal distension, shortness of breath. - Thromboembolic events: rare blood clot formation. - Allergic reaction: rash, urticaria, or anaphylaxis.

When using Menopur, clinicians should observe several safety measures.

- Patient selection: assess ovarian reserve and risk factors for OHSS before initiating therapy. - Monitoring: perform regular ultrasound and estradiol measurements to adjust dose and detect hyperstimulation. - Contraindications: avoid use in pregnancy, known hypersensitivity to menotrophin, or active ovarian cysts. - Drug interactions: review concomitant medications that may affect ovarian response, such as clomiphene or GnRH analogues. - Pregnancy testing: confirm negative pregnancy test prior to starting treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other agents that influence ovarian function.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended gonadotropin response. - High‑dose estrogen therapy: can interfere with follicular development. - Certain chemotherapy agents: may exacerbate ovarian toxicity.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: additive stimulation may increase OHSS risk. - Letrozole: combined use may alter estrogen dynamics. - Anticoagulants: monitor for thrombotic events if severe OHSS develops.